Gerard Aurigemma to Endocardium
This is a "connection" page, showing publications Gerard Aurigemma has written about Endocardium.
Connection Strength
0.214
-
Aurigemma GP, Meyer TE, Sharma M, Sweeney A, Gaasch WH. Evaluation of extent of shortening versus velocity of shortening at the endocardium and midwall in hypertensive heart disease. Am J Cardiol. 1999 Mar 01; 83(5):792-4, A10.
Score: 0.154
-
Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol. 1995 Jul; 26(1):195-202.
Score: 0.030
-
Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahl?f B, Aurigemma GP, Rokkedal JE, Devereux RB. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens. 2010 Jul; 28(7):1541-6.
Score: 0.021
-
Grayburn PA, Weiss JL, Hack TC, Klodas E, Raichlen JS, Vannan MA, Klein AL, Kitzman DW, Chrysant SG, Cohen JL, Abrahamson D, Foster E, Perez JE, Aurigemma GP, Panza JA, Picard MH, Byrd BF, Segar DS, Jacobson SA, Sahn DJ, DeMaria AN. Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms. J Am Coll Cardiol. 1998 Jul; 32(1):230-6.
Score: 0.009